Summary
• Pasithea Therapeutics Corp. (KTTA) sees a 12% decline in pre-market trading, dropping to $0.93 from $1.06.
• The company reports positive safety outcomes from its completed Phase 1 trial for PAS-004, with no adverse events noted.
• Analyst consensus remains optimistic with a “Buy” rating, despite the stock’s year-to-date decline of 78.1%.
Pasithea Therapeutics Corp. (KTTA) is experiencing a notable pre-market decline of 12%, dropping to a current price of $0.93 from the last close of $1.06. This movement occurs without a clear catalyst, reflecting a routine trading environment.
Recent Developments on Clinical Trials
Despite the recent price action, Pasithea has made significant announcements regarding its Phase 1 trials. The company reported the completion of Cohort 7 for its PAS-004 treatment in advanced cancer patients, highlighting positive safety outcomes along with pharmacokinetic and pharmacodynamic data. Notably, no treatment-related adverse events were observed during the trial’s designated period, showcasing the treatment’s safety profile.
The trial continues to demonstrate encouraging results, including a consistent pharmacokinetic profile. Noteworthy findings indicate dose-proportionality in pharmacokinetic data, potentially solidifying the drug’s position within its competitive landscape.
Regulatory Filings
On November 25, Pasithea filed an 8-K detailing recent operational updates. The document may provide further insights into upcoming plans or necessary disclosures following their ongoing clinical trial progress.
Market and Technical Picture
Currently, KTTA is operating below its 20-day simple moving average of 57% while also underperforming relative to its 50-day and 200-day SMAs, which stand at 47.75% and 14.97%, respectively. The stock has faced substantial downward pressure throughout the year, with a year-to-date performance of -78.1%. Additionally, the average volume over the last 10 days is notably high at approximately 33.34 million shares, indicating active trading despite recent price declines.
Analyst Sentiment
Analyst consensus for Pasithea remains optimistic with a “Buy” rating. This sentiment reflects confidence in the company’s long-term growth potential, especially in light of its recent clinical trial advancements.
With the latest update now reflected in trading, investors will be monitoring how the stock’s volume and momentum develop in the next session.